“We are very pleased to bring Peter Wulff onto our executive team as Vice President of Finance and Chief Financial Officer,” said David Macdonald, CEO of Agendia. “Peter is a results-driven leader, with an excellent reputation. His proven financial leadership experience will be instrumental in our ability to meet our business goals.”
Wulff has over 25 years of experience with financial management and corporate governance in the life sciences industry, including over 12 years of C-level experience primarily in medical device companies. He has demonstrated success in building and directing responsive operational infrastructure and financial reporting systems in both multinational and start-up operating environments of public and privately-held companies through a total team approach. He has extensive background in raising capital through both public and private equity offerings, various types of debt financing and strategic business transactions.
“Having met with David and the rest of the team, I am impressed by everyone’s drive and the sense of purpose embedded in the corporate culture here at Agendia,” said Wulff. “Agendia’s state of the art technology and world-class team of experts is achieving unprecedented results in the field of genomic profiling for cancer patients. I’m excited to be a contributor in this effort.
Wulff immigrated to the U.S. from the Netherlands and earned a B.A. in both Economics and Germanic Languages and an M.B.A. in Finance from Indiana University. He is a Certified Management Accountant and a member of numerous professional and civic organizations. He will share his time between Agendia’s Amsterdam and Irvine, California locations.
About Agendia:
Agendia is a leading molecular diagnostics company that develops and markets genomic-based products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia’s Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient’s tumor and provides unprecedented biological insight to address complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 gene expression assay, and TheraPrint®, a therapy selection assay. Together, these tests help physicians determine a patient’s individual risk for metastasis, which patients will benefit from chemo, hormonal or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.
Agendia is based in Irvine, California, United States, and Amsterdam, the Netherlands. For more information, please visit www.agendia.com.
Agendia BV
1098 XH, Amsterdam
Phone: +31 (20) 4621500, www.agendia.com/
Sector: Biotechnology / R&D Services
Description: Agendia is committed to improving the quality of life of people suffering from cancer through enabling effective personalized medicine. The company is pioneering the development and commercialization of validated tests that assist healthcare professionals and pharmaceutical companies to determine the diagnosis, prognosis and therapeutic responsiveness of cancers in individual patients.